Michael Gordon

Michael Gordon is an experienced finance professional currently serving as Executive Director of Financial Planning and Analysis (FP&A) at ImmunoGen, Inc. since February 2021, after previously holding the position of Senior Director of FP&A. Prior to this role, Michael held various positions at Shire from 2011 to January 2020, culminating as Head of Finance for Ophthalmics, US Immunology (HAE), and US Commercial Operations, where notable accomplishments included financial oversight for the successful launch of the product Xiidra. Michael's earlier experience includes finance roles at Merck and ARAMARK, where responsibilities included financial support and analysis for sales, discounts, and budgeting processes. Michael holds an MBA in Marketing from Villanova University and a Bachelor of Science in Finance with International Studies from Penn State University.